TABLE 3.

Random-effects meta-regression to investigate the reason for heterogeneity of the percentage of therapeutic interventions in all endoscopic retrograde cholangiopancreatography (ERCP) procedures.

_meta_es	Coef.	Std. err.	z	P > | z|	[95% Confidence interval]
Country subtype	0.0597887	0.0386503	1.55	0.122	−0.01596450.1355418
Disease subtype	0.0097363	0.0140803	0.69	0.489	−0.01786050.0373331
Year subtype	−0.0744469	0.0267981	−2.78	0.005	−0.1269702–0.0219237
Study design subtype	0.0334285	0.0718178	0.47	0.642	−0.10733170.1741887
_cons	0.7616619	0.0937192	8.13	0.000	0.57797580.9453481

Test of residual homogeneity: Q_res = chi2(5) = 5.47 Prob > Q_res = 0.3618.

Number of obs = 10.

Method: REML.

Residual heterogeneity:

tau2 = 0.000253.

I2 (%) = 16.62.

H2 = 1.20.

R-squared (%) = 78.08.

Wald chi2(4) = 10.07.

Prob > chi2 = 0.0393.

Country subtype:

1: Occident countries (the United States, France, Belgium, etc.).

2: Orient countries (China, Japan, South Korea, etc.).

Disease subtype:

1: HPB system diseases, which include all pediatric hepatic, pancreatic, and biliary diseases.

2: Pancreatic diseases.

3: Hepatobiliary diseases.

4: Complications after liver, intestine, or composite abdominal organ transplantation.

Year subtype:

1: Publications in the last 10 years (2012–2022).

2: Publications in the last 10–20 years (2002–2012).

3: Articles published 20 years ago.

Study subtype:

1: Retrospective study.

2: Prospective study.